Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. - Wikidata - awgldk - TriplyDB

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

http://www.wikidata.org/entity/Q43048164

about

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice Older patients with myeloma derive similar benefit from autologous transplantation.Time-dependent endpoints as predictors of overall survival in multiple myeloma Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Review of health-related quality of life data in multiple myeloma patients treated with novel agents.Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer.Multiple myeloma in the older adult: better prospects, more challenges.Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.IMWG consensus on maintenance therapy in multiple myeloma.Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.European perspective on multiple myeloma treatment strategies: update following recent congresses The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Senior adult oncology.Challenges in multiple myeloma diagnosis and treatment.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.Treatment of multiple myeloma in the elderly: realities and hopes.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Treatment of newly diagnosed myeloma in patients not eligible for transplantation.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.Multiple myeloma treatment strategies with novel agents in 2011: a European perspective Managing multiple myeloma in the elderly: are we making progress?Bortezomib for previously untreated multiple myeloma.

P2860

Q26767418-D009C311-98DA-4D9B-9556-92C4A9901476 Q26998884-C8B08713-CE02-4032-BAA4-7A68658896ED Q27002668-0C46338B-1AB1-4FC5-9B3A-CD802FF7CAD0 Q27008491-3F5E1708-0898-4E15-8D76-BA1C04C83CFB Q28077567-EB54B0F7-96CB-4118-A9A2-673C2BE70D27 Q30370038-7AFF4D05-5EDA-4642-ADB0-68A4555474F1 Q30538040-481A0578-4933-474D-863F-6903B75AA558 Q30595175-AC5484F3-B7D8-418C-BD29-861FFF1FC7F5 Q30650394-5A103EC1-B459-44A5-8122-48E3B5B8F4E3 Q33564241-D1C64F9C-6C49-4C82-9C1C-60422892B056 Q34031129-225B1B3B-AE04-4175-B15F-2643EB2348E7 Q34038959-F754C783-DCA8-4AA6-ADDE-8959D5620772 Q34253548-6FD8BF1B-09E7-4C0F-BCE3-0C05E3AEB61E Q34372086-A0B3FD73-4621-4857-AFA7-443B7024CDAB Q35153760-6EE863C5-C3B5-442C-BA7D-B350F3337B9C Q35631904-8BCDC510-1E82-43EF-AB1E-BEAC5FBA16DF Q35669893-1A29F102-8F8D-41FF-8A5D-2889290E6447 Q35876966-7CB765F7-7403-4572-991E-F6C87C8C4A2D Q35932505-7BC57924-7ACA-4477-9A88-1F10EA562542 Q35989943-95A289C4-5BF3-465D-A7D3-E72514871E3E Q36565628-BDC3EFE0-BCF2-43BD-83DE-2AEFD67DF8F8 Q36612613-58414FA3-03DE-4F85-94E8-AD13D7297037 Q36654092-57BD2E83-8F0A-4C8B-BCA9-12FB52E48B85 Q36706899-3746E98F-A7D5-42A8-BE68-E08D8CB1475A Q36777233-E6B3B28B-5D1E-4889-901A-92DD5E1A3B05 Q36851424-A51FD89D-DAB7-4A36-83DD-67306A74ECEA Q36852225-C5B2EFC4-159F-4B8F-B50C-06C4B474C855 Q36963203-0563F3F8-3273-460F-9F21-4762A8AE8B73 Q37228026-F6AB9246-3BC4-4314-BCAA-18594F50BC90 Q37536148-4A116D47-79A7-46F4-8E7D-AE24D25F98B3 Q37623809-CF23B347-64A5-481A-8BDE-7B6501739DBD Q37724272-97776CE7-D490-4EC8-81AB-9B288AA8A5E9 Q37809535-D4BAFF6A-88C4-4265-99C3-B7EFC70014DB Q37842346-A9AC20F0-5C13-4CBD-95D3-0D401B2B48CB Q37846567-5BACF0D5-6B6F-463F-BA4B-BE3B41D5E123 Q37851944-8C1DD660-40CD-4179-8866-0C1AC74FF887 Q37857784-D102B786-4E10-4DBB-97CA-BE7A3BFE66C5 Q37858327-536D2D2E-ECD3-427C-946E-C6405083873C Q37888716-C2EACC6B-E680-41AF-A3B0-5243024A92F8 Q37937699-9D9E925E-74BE-49FC-B3F1-3B8ADF174D13

P2860

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

http://www.wikidata.org/entity/Q43048164

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Phase III study of the value o ...... e myeloma: the HOVON 49 Study.

@en

Phase III study of the value o ...... e myeloma: the HOVON 49 Study.

@nl

type

label

Phase III study of the value o ...... e myeloma: the HOVON 49 Study.

@en

Phase III study of the value o ...... e myeloma: the HOVON 49 Study.

@nl

prefLabel

Phase III study of the value o ...... e myeloma: the HOVON 49 Study.

@en

Phase III study of the value o ...... e myeloma: the HOVON 49 Study.

@nl

P1433

Q43048164-D4951DFD-0A8D-47A5-9A87-169083B9AE3A

P1476

Q43048164-477578DA-6298-43B6-A3A0-A98D24E08BD5

P2093

Q43048164-09A99073-145E-4AE9-BF46-2837F255375D

Q43048164-208515C3-5246-456F-8B78-97F2C660A4F6

Q43048164-21029825-7EB9-445C-A36C-6E94765ABB7D

Q43048164-2386EA5C-6AB3-4F7F-87D7-188756BFE84C

Q43048164-2E8B7AF5-B041-401E-BA56-EB6A09C53903

Q43048164-62415174-1C74-4B72-A815-D879B047A92C

Q43048164-6F12105E-13D0-4BBC-889C-6557F5E96C35

Q43048164-85A14FCE-92FD-4C4A-AAAC-2DF752F4AD96

Q43048164-9D0710A1-6DD0-470E-8335-DEFAE275B82A

Q43048164-A66F1077-1F48-4D25-84D3-B5E362A7D2EF

P304

Q43048164-8316E07C-53CA-41F9-95B2-747FD5A80CBF

P31

Q43048164-888C56E8-EC3E-4516-B916-A257CCCB16C0

P356

Q43048164-C454CDA3-C875-4F81-B3FA-98D1D915D461

P407

Q43048164-AB5F681E-860F-48FE-AC9C-2213B58A8B4A

P433

Q43048164-D8F08602-F193-4092-998F-5A2D1DCC5EC1

P478

Q43048164-CAF674C8-8DB0-4CF1-904E-ACA03325BF41

P50

Q43048164-1B5CEA93-45A1-4D8B-AD40-83391BFB0E51

P577

Q43048164-EBC523F8-5F31-4848-BCEB-2E0D5C9CCEA0

P698

Q43048164-DCC01EA8-1ED8-405A-BD46-9AD778F06A8B

P921

Q43048164-79503620-4466-45AF-910D-9FC4D238FEBF

Q43048164-8D1E4F8A-8B74-4474-B34C-8FFC20009661

P356

JCO.2009.26.1610

P1433

Journal of Clinical Oncology

P1476

Phase III study of the value o ...... e myeloma: the HOVON 49 Study.

@en

P2093

Dutch-Belgium Cooperative Group HOVON

http://www.w3.org/2001/XMLSchema#string

Fabian Termorshuizen

http://www.w3.org/2001/XMLSchema#string

Harm Sinnige

http://www.w3.org/2001/XMLSchema#string

Henk Lokhorst

http://www.w3.org/2001/XMLSchema#string

Marinus van Marwijk Kooy

http://www.w3.org/2001/XMLSchema#string

Martijn Schaafsma

http://www.w3.org/2001/XMLSchema#string

Pierre Wijermans

http://www.w3.org/2001/XMLSchema#string

René van der Griend

http://www.w3.org/2001/XMLSchema#string

Rianne Ammerlaan

http://www.w3.org/2001/XMLSchema#string

Shulamiet Wittebol

http://www.w3.org/2001/XMLSchema#string

P304

3160-3166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.1610

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Pieter Sonneveld

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20516439

http://www.w3.org/2001/XMLSchema#string

P921